
    
      This is a phase II clinical trial, that administers a maintenance treatment after first line
      chemotherapy is complete. It is designed to have a 1:1 randomization technique. Half the
      participants who enter the study will receive the active ingredient, Rucaparib, while the
      other half will receive a placebo. Treatment will be until progression with follow up until
      death.
    
  